Cameron G McCarthy1, Camilla F Wenceslau2, Styliani Goulopoulou3, Safia Ogbi2, Babak Baban4, Jennifer C Sullivan2, Takayuki Matsumoto5, R Clinton Webb2. 1. Department of Physiology, Georgia Regents University, 1120 15th Street, Augusta, GA 30912, USA cmccarthy@gru.edu. 2. Department of Physiology, Georgia Regents University, 1120 15th Street, Augusta, GA 30912, USA. 3. Department of Integrative Physiology and Anatomy, and Obstetrics and Gynecology, University of North Texas Health Science Center, Fort Worth, TX, USA. 4. Department of Oral Biology, Georgia Regents University, Augusta, GA, USA. 5. Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Tokyo, Japan.
Abstract
AIMS: Immune system activation is a common feature of hypertension pathogenesis. However, the mechanisms that initiate this activation are not well understood. Innate immune system recognition and response to danger are becoming apparent in many cardiovascular diseases. Danger signals can arise from not only pathogens, but also damage-associated molecular patterns (DAMPs). Our first hypothesis was that the DAMP, mitochondrial DNA (mtDNA), which is recognized by Toll-like receptor 9 (TLR9), is elevated in the circulation of spontaneously hypertensive rats (SHR), and that the deoxyribonuclease enzymes responsible for its degradation have decreased activity in SHR. Based on these novel SHR phenotypes, we further hypothesized that (i) treatment of SHR with an inhibitory oligodinucleotide for TLR9 (ODN2088) would lower blood pressure and that (ii) treatment of normotensive rats with a TLR9-specific CpG oligonucleotide (ODN2395) would cause endothelial dysfunction and increase blood pressure. METHODS AND RESULTS: We observed that SHR have elevated circulating mtDNA and diminished deoxyribonuclease I and II activity. Additionally, treatment of SHR with ODN2088 lowered systolic blood pressure. On the other hand, treatment of normotensive rats with ODN2395 increased systolic blood pressure and rendered their arteries less sensitive to acetylcholine-induced relaxation and more sensitive to norepinephrine-induced contraction. This dysfunctional vasoreactivity was due to increased cyclooxygenase and p38 mitogen-activated protein kinase activation, increased reactive oxygen species generation, and reduced nitric oxide bioavailability. CONCLUSION: Circulating mtDNA and impaired deoxyribonuclease activity may lead to the activation of the innate immune system, via TLR9, and contribute to elevated arterial pressure and vascular dysfunction in SHR. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Immune system activation is a common feature of hypertension pathogenesis. However, the mechanisms that initiate this activation are not well understood. Innate immune system recognition and response to danger are becoming apparent in many cardiovascular diseases. Danger signals can arise from not only pathogens, but also damage-associated molecular patterns (DAMPs). Our first hypothesis was that the DAMP, mitochondrial DNA (mtDNA), which is recognized by Toll-like receptor 9 (TLR9), is elevated in the circulation of spontaneously hypertensiverats (SHR), and that the deoxyribonuclease enzymes responsible for its degradation have decreased activity in SHR. Based on these novel SHR phenotypes, we further hypothesized that (i) treatment of SHR with an inhibitory oligodinucleotide for TLR9 (ODN2088) would lower blood pressure and that (ii) treatment of normotensive rats with a TLR9-specific CpG oligonucleotide (ODN2395) would cause endothelial dysfunction and increase blood pressure. METHODS AND RESULTS: We observed that SHR have elevated circulating mtDNA and diminished deoxyribonuclease I and II activity. Additionally, treatment of SHR with ODN2088 lowered systolic blood pressure. On the other hand, treatment of normotensive rats with ODN2395 increased systolic blood pressure and rendered their arteries less sensitive to acetylcholine-induced relaxation and more sensitive to norepinephrine-induced contraction. This dysfunctional vasoreactivity was due to increased cyclooxygenase and p38 mitogen-activated protein kinase activation, increased reactive oxygen species generation, and reduced nitric oxide bioavailability. CONCLUSION: Circulating mtDNA and impaired deoxyribonuclease activity may lead to the activation of the innate immune system, via TLR9, and contribute to elevated arterial pressure and vascular dysfunction in SHR. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Weike Bao; David J Behm; Sandhya S Nerurkar; Zhaohui Ao; Ross Bentley; Rosanna C Mirabile; Douglas G Johns; Tina N Woods; Christopher P A Doe; Robert W Coatney; Jason F Ohlstein; Stephen A Douglas; Robert N Willette; Tian-Li Yue Journal: J Cardiovasc Pharmacol Date: 2007-06 Impact factor: 3.105
Authors: Tomasz J Guzik; Nyssa E Hoch; Kathryn A Brown; Louise A McCann; Ayaz Rahman; Sergey Dikalov; Jorg Goronzy; Cornelia Weyand; David G Harrison Journal: J Exp Med Date: 2007-09-17 Impact factor: 14.307
Authors: Cameron G McCarthy; Camilla F Wenceslau; Styliani Goulopoulou; Safia Ogbi; Takayuki Matsumoto; R Clinton Webb Journal: Pharmacol Res Date: 2016-09-14 Impact factor: 7.658
Authors: Brandi M Wynne; Cameron G McCarthy; Theodora Szasz; Patrick A Molina; Arlene B Chapman; R Clinton Webb; Janet D Klein; Robert S Hoover Journal: J Hypertens Date: 2018-03 Impact factor: 4.844
Authors: Justine M Abais-Battad; John Henry Dasinger; Daniel J Fehrenbach; David L Mattson Journal: Pharmacol Res Date: 2017-03-20 Impact factor: 7.658
Authors: Cameron G McCarthy; Camilla F Wenceslau; Styliani Goulopoulou; Babak Baban; Takayuki Matsumoto; R Clinton Webb Journal: Am J Hypertens Date: 2016-09-13 Impact factor: 2.689